Find relevant news articles from other European projects, below:
Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:
Multiorgan Immune-Related Adverse Events During Treatment With Atezolizumab
Immune checkpoint inhibitors (ICIs) commonly target CTLA-4, PD-1, and PD-L1, which promote inhibitory signals on immune effector T cells against cancer cells. Although ICIs have improved outcomes in several cancers, their use is also associated with significant adverse events (AEs), including death.
CAR T-Cell Optimization Starts in Production, Extends to Therapy
New technologies allow finer control of CAR T cells at every level—manufacturing, assessments of tissue penetrance, targeting, potency, and dosing.
Targeted Therapy Combinations With JAK inhibition Show Early Promise for Myelofi...
Patients with myelofibrosis have complicated pathology and multiple pathways, creating the opportunity to use multiple targeted agents for treatment, but also leading to greater potential for resistance to monotherapy, according to Lucia Masarova, MD.
New tool identifies which cancer patients are most likely to benefit from immuno...
A new diagnostic tool that can predict whether a cancer patient would respond to immunotherapy treatment has been developed. This advance in precision medicine will allow clinicians to tailor treatments specifically to patients and avoid treatment paths that are unlikely to be successful.
EHA CAR-T Program
EHA is committed to providing accessible and relevant education for all. As part of a new immunotherapy program, EHA is launching an Immunotherapy learning path on the EHA Campus, where CAR-T is the first topic addressed.
Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the eff...
Immunotherapies that target programmed cell death protein 1 (PD-1) and its ligand PD-L1 as well as cytotoxic T-lymphocyte-associated protein 4 (CTLA4) have shown impressive clinical outcomes for multiple tumours.
Checkpoint Molecule Could Be New Cancer Immunotherapy Target
A team of researchers at the German Cancer Research Center (DKFZ) and the Berlin Institute of Health (BIH) have released new data that highlights a potential new target for cancer immunotherapies. The scientists found that the metabolic enzyme IL4I1 (Interleukin-4-Induced-1) promoted the spread of tumor cells and suppressed the immune system.
Why young and female patients don't respond as well to cancer immunotherapy
Empowering a patient's own immune system to clear away tumors on its own, holds great promise for some patients. But for other patients, immunotherapy just doesn't work.
Infection during the first year in patients treated with CD19 CAR T cells for di...
CD19-targeted chimeric antigen receptor (CAR) T cell therapy is an effective treatment for diffuse large B cell lymphoma (DLBCL).
FDA Approves First Cell-Based Gene Therapy For Adult Patients with Relapsed or R...
The U.S. Food and Drug Administration approved Tecartus, a cell-based gene therapy for treatment of adult patients diagnosed with mantle cell lymphoma (MCL) who have not responded to or who have relapsed following other kinds of treatment.